IL-22 (F-652) Placebo

Phase 2

IL-22 (F-652) Placebo is one of 4 therapeutic programs targeting Alcohol-Associated Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alcohol-Associated HepatitisRecruiting

Alcohol-Associated HepatitisPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Alcohol-Associated Hepatitis

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 2

1 2

Campral

FForest Laboratories

Phase 2

1 3

IL-22

SSamer Gawrieh

Phase 2

1 4

IL-22 (F-652) Placebo

SSamer Gawrieh

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Alcohol-Associated Hepatitis

NCT07060638

Clinical

Trials by Indication[1]

Alcohol-Associated Hepatitis1 trial

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Recruiting·SSamer Gawrieh·Phase 2·NCT07060638·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IL-22 (F-652) Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for IL-22 (F-652) Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Samer Gawrieh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSamer Gawrieh

IL-22 (F-652) Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Alcohol-Associated Hepatitis1 trial

References

Drug Info

Quick Facts

Related News